Long-Term Debt: Liminatus Pharma Corp (LIMN)

Liminatus Pharma (LIMN) is actively developing CAR-T therapy and CD47 inhibitors, currently positioned in a phase of early technological breakthrough. Current price action reflects the 0.00 indicator. The business relies on unique tumor-fighting patents, which promises stable payments from pharma behemoths. However, military conflicts and sanctions are currently complicating the transportation of biomaterials, significantly slowing down global research and drug registration.

Long-term debt measures total borrowed capital with a maturity of more than one year, where a stable plateau of the indicator suggests an absence of emergency lending and a low risk of default. By analyzing the volume of the corporation's long-term loans and borrowings for a portfolio stress test, an investor will see the financial stability of Liminatus Pharma (LIMN), whose operating losses prior to the launch of the solid tumor therapy are already priced in by the market.